Cover Image
市場調查報告書

A型血友病的全球市場:2015∼2019年

Global Hemophilia A Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 341165
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
A型血友病的全球市場:2015∼2019年 Global Hemophilia A Market 2015-2019
出版日期: 2015年09月30日 內容資訊: 英文 68 Pages
簡介

血友病是缺乏第VIII或第IX等凝血因子造成的罕見血液疾病。女性罹患率比男性為高,預測一年將有40萬人罹患該病。全球A型血友病市場預測在2014∼2019年間將以年複合成長率6.25%擴大。

本報告提供全球A型血友病市場現狀及2015∼2019年的成長預測相關調查,為您彙整市場規模,收益趨勢,各產品,各地區趨勢,及主要供應商簡介等資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • A型血友病的理解
  • 風險因素
  • 症狀
  • 診斷
  • 治療
  • 流行病學

第6章 產品研發線

第7章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各個治療市場區隔

  • 血漿原來治療
  • 組調換治療

第9章 疾病管理別市場區隔

  • 隨選治療
  • 預防法
  • 抑制劑

第10章 各地區市場區隔

第11章 推動市場的要素

第12章 推動市場要素的影響

第13章 市場課題

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2014年
  • 其他值得注意的供應商

第17章 主要供應商分析

  • Baxter
  • Bayer HealthCare
  • CSL Behring
  • Pfizer

第18章 附錄

第19章 關於Technavio

圖表

目錄
Product Code: IRTNTR7382

About hemophilia A

Hemophilia is a rare bleeding disorder caused by deficiency of clotting factors such as VIII and IX. It is an X-linked recessive disorder, which is more prevalent in males than in females. It is estimated that it affects around 400,000 people per year. The two major types of hemophilia are A and B. Hemophilia A, also called as classical hemophilia or factor VIII deficiency hemophilia, is caused by deficiency of clotting factor VIII. It is transmitted genetically from parent to child during birth. Recombinant clotting factors or plasma-derived clotting factors are being developed for the treatment of this disorder.

Technavio's analysts forecast the global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy.

Technavio's report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • Europe

Key vendors

  • Baxter International
  • Bayer's
  • CSL Behring
  • Novo Nordisk
  • Pfizer

Other Prominent Vendors

  • Alnylam Pharmaceuticals
  • Amarna Therapeutics
  • Asklepios
  • Biogen Idec
  • Catalyst Biosciences
  • Dimension Therapeutics
  • Dong-A Socio
  • Emergent BioSolutions
  • Grifols
  • Inspiration Biopharmaceuticals
  • Kedrion Biopharma
  • Octapharma
  • OPKO Health
  • rEVO Biologics
  • Sangamo BioSciences
  • Spark Therapeutics
  • UniQure

Market driver

  • Development of drugs with prolonged action
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Advances in technology
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Risk factors
  • Signs and symptoms
  • Diagnosis
  • Treatment
  • Epidemiology

PART 06: Pipeline portfolio

  • Key information on pipeline candidates

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Segmentation by type of therapy

  • Plasma-derived therapies
  • Recombinant therapies

PART 09: Segmentation by disease management

  • On-demand therapy
  • Prophylaxis
  • Inhibitors

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 17: Key vendor analysis

  • Baxter
  • Bayer HealthCare
  • CSL Behring
  • Pfizer

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Number of prevalence cases of hemophilia A in five countries 2011
  • Exhibit 03: Key late-stage drugs under development for hemophilia A
  • Exhibit 04: Global hemophilia A drugs market 2014-2019 ($ billions)
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Global hemophilia A drugs market by type of therapy
  • Exhibit 07: Segmentation by type of therapy for hemophilia A
  • Exhibit 08: Global hemophilia A drugs market by disease management
  • Exhibit 09: Types of prophylaxis
  • Exhibit 10: Segmentation by disease management of hemophilia A
  • Exhibit 11: Segmentation of global hemophilia A drugs market by geography in 2014
  • Exhibit 12: Impact of drivers
  • Exhibit 13: Impact of drivers and challenges
  • Exhibit 14: Baxter: Global YoY growth and revenue of hemophilia products 2012-2014 ($ millions)
  • Exhibit 15: Baxter: Key takeaways
  • Exhibit 16: Novo Nordisk: Global YoY growth and revenue of hemophilia products 2012-2014 ($ millions)
  • Exhibit 17: Novo Nordisk: Key takeaways
  • Exhibit 18: Bayer: Global YoY growth and revenue of Kogenate FS 2012-2014 ($ millions)
  • Exhibit 19: Bayer's: Key takeaways
  • Exhibit 20: Pfizer: Global YoY growth and revenue of Xyntha/ReFactoAF 2012-2014 ($ millions)
  • Exhibit 21: Pfizer: Key takeaways
  • Exhibit 22: CSL Behring: Global YoY growth and revenue of hemophilia products 2013-2014 ($ millions)
  • Exhibit 23: CSL Behring: Key takeaways
  • Exhibit 24: CSL Behring: Product segmentation by revenue 2014
  • Exhibit 25: CSL Behring: Geographical segmentation by revenue 2014
  • Exhibit 26: Novo Nordisk: Business segmentation by revenue 2014
  • Exhibit 27: Novo Nordisk: Business segmentation by revenue 2013 and 2014
  • Exhibit 28: Novo Nordisk: Geographical segmentation by revenue 2014
  • Exhibit 29: Novo Nordisk: R&D expenditure 2014
Back to Top